PremiumCompany AnnouncementsFibroGen Amends Financing Agreement for Flexibility FibroGen’s Earnings Call: Strategic Gains Amid Revenue Woes FibroGen’s Strategic Positioning and Financial Health: A Buy Rating Backed by Strong Cash Reserves and Promising Clinical Pipeline PremiumThe FlyBiotech Alert: Searches spiking for these stocks today FibroGen’s Earnings Call: Strategic Moves Amid Challenges FibroGen’s Strategic Financial Moves and Promising Clinical Developments Drive Buy Rating PremiumPre-EarningsIs FGEN a Buy, Before Earnings? FibroGen’s Strategic Sale and Pipeline Focus Justify Buy Rating Amid Financial Strength FibroGen China sale ‘shrewd strategic transaction,’ says H.C. Wainwright 
